ClinicalTrials.gg
CompletedNCT02467517KETAPAINUpdated Nov 9, 2026

Ketamine and Neuropathic Pain

A Phase 2 interventional study of Ketamine and Magnesium Sulfate in Neuropathic Pain, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedResults publication added+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing ketamine in Neuralgia — 1 open to participants now, 1 under way, none of them phase 3. Ketamine · Neuralgia.

Enrollment
10th of 12
23 · median 38
Started
2015
with 1 other
Phase 2
4 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
University Hospital, Clermont-Ferrand

Among the 12 studies testing ketamine in Neuralgia, this one is the 10th largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 2, and was the 7th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

1 of the 12 studies testing ketamine in Neuralgia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing ketamine in Neuralgia, or all of them as a file.
02

Study summary

The primary outcome is to compare the analgesic efficacy of intravenous ketamine treatment to that of a placebo in patients with refractory neuropathic pain.

The secondary outcomes are:

  1. - To compare the additive analgesic efficacy of prior administration of magnesium sulfate to that of placebo and ketamine only, on the effectiveness of intravenous ketamine treatment,
  2. - To study the evolution time of pain and analgesia after the intravenous administration of ketamine and placebo,
  3. - To study the correlation of the analgesic response to administered products respectively ketamine, ketamine and magnesium sulfate, placebo.
Read the detailed description

Description of the study:

Single-center clinical trial, controlled, randomized, double-blind, crossover design, against inactive placebo.

Each patient will receive successively the 3 products (ketamine / placebo, ketamine / magnesium sulfate, placebo / placebo) follows a predeter randomization list, with a wash-out period between each administration.

Visit 1

-Inclusion visit, signature of informed consent form, clinical examination and fill questionnaires.

For women of childbearing age a pregnancy test will be performed.The pain will be measured by a numerical scale.

The pain will be evaluated by scoring on a numerical scale. A booklet for monitoring analgesic concomitant medication and overall pain on a numerical scale will be given to the patient 14 days before the programmed infusion.

Visit 2 : Period 1 Day 0

Clinical examination, return of booklet completed by patient and fill questionnaires.

The pain will be evaluated by scoring on a numerical scale before and after the infusion.

For women of childbearing age a pregnancy test will be performed. Treatment allocation period follows a predeter randomization list. At the end of the infusion, a booklet for monitoring will be given to patients for the following weeks in order to score their overall pain until the next study period.

The output of the hospital patient (CPC / CETD) after each treatment will be authorized by the investigator.

Wash-out period: 5 weeks.

Phone call 1 (Day 1):

Patients will be called by phone to collect adverse events and concomitant medications. If necessary, the patients should return to consult the CPC / CETD for a clinical examination.

Patients will be called the week before their scheduled visit, if at that time their spontaneous pain is still low, according to the opinion of the investigator, the infusion visit will be shifted to allow the pain level back its basal level.

Visit 3 : Period 2 : Day 36 +/- 3 days

Same of period 1.

Phone call 2 J 37 +/- 3 days:

Same of phone call 1.

Visit 4 : Period 3 : Day 72 +/- 3 days

Same of period 1

Phone call 3 J 73 +/- 3 days:

Same of phone call 1.

Visit 5 : Day 108 +/- 3 days

Clinical examination, return of booklet completed by patient and fill questionnaires.

The pain will be evaluated by scoring on a numerical scale For women of childbearing age a pregnancy test will be performed. This visit is the end of the study.

03

Conditions studied

  • Neuropathic Pain

Keywords

  • Neuropathic pain
  • Ketamine
  • Magnesium sulfate
  • Quality of life
  • Anxiety and depression
  • Mood and sleep
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient (s) are at least18 years old, with chronic pain (for more than 3 months), having the characteristics of a peripheral or central neuropathy, follow (s) at the Pain Clinic CHU Clermont-Ferrand and justifying the establishment of a therapeutic program including intravenous infusion of ketamine (as therapeutic test);
  • Patient (s) who had never received ketamine infusion under the care of their neuropathic pain;
  • History of illness compatible with an injury or disease of the somatosensory system;
  • Localized pain in an anatomical neuro territory;
  • Neurological examination shows sensory abnormalities,
  • The patients of must use effective throughout the study;
  • For womens of childbearing age, they will be enrolled in the study after a negative urine pregnancy test; in case of suspicion of pregnancy, a blood pregnancy test should be performed;
  • Cooperation and willing to follow the study;
  • Acceptance to give written consent;
  • Affiliated to the French social security;
  • Inscription or acceptation of inscription in the national register of volunteers involved in trials.

Exclusion criteria

Exclusion Criteria:

  • Patient (s) who have received intravenous ketamine infusion;
  • Patients with one or many to ketamine administration: known to ketamine in which one of the constituents of the product, uncontrolled high blood pressure, severe cardiac insufficiency;
  • Patients with one or many contraindication of magnesium sulfate administration: Patients with severe renal impairment;
  • Patients with one or many contraindication to administration of sodium chloride: water inflation, fluid retention;
  • Patients with a medical history and / or surgical judged by the investigator to be not consistent with the clinical trial;
  • Patients with drug treatments judged by the investigator to be not consistent with the clinical trial;
  • Pregnancy or lactation women;
  • Patient who participated in another clinical trial, located in exclusion period or received benefits > 4500 euros during 12 months before the beginning of trial;
  • Patients with cooperation and understanding not to adhere strictly to the conditions provided in the clinical trial;
  • Patients receiving a measure of legal protection (guardianship…);
  • Patients are not affiliated to the System of the French Social Security
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    INTRAVENOUS KETAMINE

    Drug: Ketamine · Drug: Magnesium Sulfate · Drug: placebo : sodium chloride

Interventions

06

What researchers measure

Primary outcomes

  1. Numerical rating scale (NRS)

    Time frame: at day 1 and for a period of 5 weeks (35 days).

Secondary outcomes

  1. Intensity of the average

    Intensity of the average daily pain evaluated by a numerical rating scale (NRS) assessed using a booklet

    Time frame: at day 1

  2. Intensity of maximum daily pain

    Intensity of maximum daily pain evaluated by a numerical rating scale (NRS) assessed using a booklet,

    Time frame: at day 1

  3. Impact on quality of life

    Impact on quality of life, mood and sleep assessed by questionnaires.

    Time frame: at day 1

  4. Impact on mood

    Impact on quality of life, mood and sleep assessed by questionnaires.

    Time frame: at day 1

  5. Impact on sleep

    Impact on quality of life, mood and sleep assessed by questionnaires.

    Time frame: at day 1

07

Study locations

1 site
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Pickering G, Pereira B, Morel V, Corriger A, Giron F, Marcaillou F, Bidar-Beauvallot A, Chandeze E, Lambert C, Bernard L, Delage N. Ketamine and Magnesium for Refractory Neuropathic Pain: A Randomized, Double-blind, Crossover Trial. Anesthesiology. 2020 Jul;133(1):154-164. doi: 10.1097/ALN.0000000000003345. PubMed 32384291 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in May 2018, 30 months.

Of 58 phase 2 interventional studies under Neuralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's 30 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Mar 2018 → May 2018 and completion Apr 2018 → Nov 2018.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2015
First posted
Jun 10, 2015
StartActual
Nov 10, 2015
Primary completionActual
May 13, 2018was Mar 2018
CompletionActual
Nov 13, 2018was Apr 2018
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 9, 2026
Primary completion
Mar 2018→May 13, 2018 (actual)
Nov 9, 2026
Study completion
Apr 2018→Nov 13, 2018 (actual)
Nov 9, 2026
Enrollment
22 (estimated)→23 (actual)
Nov 9, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedPatients receiving a measure of legal protection (guardianship...…);
Nov 9, 2026
Publications
Results publication added: Pickering G, Pereira B, Morel V, Corriger A, Giron F, Marcaillou F, Bidar-Beauvallot A, Chandeze E, Lambert C, Bernard L, Delage N. Ketamine and Magnesium for… PubMed 32384291 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Status unknown→Completed
    Publications Results publication added: Pickering G, Pereira B, Morel V, Corriger A, Giron F, Marcaillou F, Bidar-Beauvallot A, Chandeze E, Lambert C, Bernard L, Delage N. Ketamine and Magnesium for… PubMed 32384291 ↗
    Primary completion Mar 2018→May 13, 2018 (now actual)
    Study completion Apr 2018→Nov 13, 2018 (now actual)
    Enrollment 22 (estimated)→23 (actual)
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedPatients receiving a measure of legal protection (guardianship...…);
    + 3 other changes: description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02467517
Responsible party
Sponsor
First posted
Jun 10, 2015
Start date
Nov 10, 2015
Primary completion
May 13, 2018
Completion
Nov 13, 2018
Last update
Nov 9, 2026

Study contacts

Gisèle PICKERING
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion